ABBV · Earnings call · 2026Q3T · Full report

Rinvoq Dermatology Market Expansion

AbbVie Inc. · 2026-10-30 · Importance 26 · Surprise 24

AbbVie expects Rinvoq to help build the alopecia areata and vitiligo markets, which management said currently generate sales in the small hundreds of millions of dollars despite high prevalence. Management described the alopecia data as showing substantial hair regrowth, including complete or 90% regrowth in some cases, and said vitiligo repigmentation continued to improve through 76 weeks. AbbVie anticipates a frontline approach for moderate-to-severe patients because these are largely untreated markets, and expects Rinvoq to have the most favorable data in its category for the foreseeable future. The company plans to expand dermatology sales forces around the world and invest in the indications, including consumer activation in the U.S.

Key facts

• AbbVie expects the combined peak sales contribution of the vitiligo and alopecia areata indications for Rinvoq to be nearly $2 billion.
• AbbVie has begun commercializing Rinvoq for vitiligo and alopecia areata in Europe and expects U.S. approvals for both indications over the next several months.
• AbbVie expects Rinvoq to be the first-ever systemic treatment for vitiligo, for patients with higher body surface area involvement.
• AbbVie anticipates a more frontline approach for Rinvoq in moderate-to-severe alopecia and vitiligo patients because there is little existing treatment to step through.
• AbbVie plans to expand its dermatology sales forces around the world to build the alopecia and vitiligo markets.
• AbbVie plans to invest in the alopecia and vitiligo indications.
• AbbVie said current sales in the alopecia and vitiligo markets are in the small hundreds of millions of dollars, despite high prevalence.
• AbbVie said alopecia data showed complete or 90% hair regrowth in some cases at rates not previously seen.